BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 33912554)

  • 1. Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases.
    Haas G; Fan S; Ghadimi M; De Oliveira T; Conradi LC
    Front Cell Dev Biol; 2021; 9():612774. PubMed ID: 33912554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution.
    Fleischer JR; Schmitt AM; Haas G; Xu X; Zeisberg EM; Bohnenberger H; Küffer S; Teuwen LA; Karras PJ; Beißbarth T; Bleckmann A; Planque M; Fendt SM; Vermeulen P; Ghadimi M; Kalucka J; De Oliveira T; Conradi LC
    Mol Cancer; 2023 Jan; 22(1):17. PubMed ID: 36691028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
    Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
    J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophils expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases resistant to anti-angiogenic therapy.
    Palmieri V; Lazaris A; Mayer TZ; Petrillo SK; Alamri H; Rada M; Jarrouj G; Park WY; Gao ZH; McDonald PP; Metrakos P
    J Pathol; 2020 Jun; 251(2):213-223. PubMed ID: 32297656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model.
    Rada M; Lazaris A; Kapelanski-Lamoureux A; Mayer TZ; Metrakos P
    Semin Cancer Biol; 2021 Jun; 71():52-64. PubMed ID: 32920126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases.
    Rada M; Kapelanski-Lamoureux A; Petrillo S; Tabariès S; Siegel P; Reynolds AR; Lazaris A; Metrakos P
    Commun Biol; 2021 Aug; 4(1):950. PubMed ID: 34376784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases.
    Rada M; Krzywon L; Petrillo S; Lazaris A; Metrakos P
    Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiopoietin1 Deficiency in Hepatocytes Affects the Growth of Colorectal Cancer Liver Metastases (CRCLM).
    Ibrahim NS; Lazaris A; Rada M; Petrillo SK; Huck L; Hussain S; Ouladan S; Gao ZH; Gregorieff A; Essalmani R; Seidah NG; Metrakos P
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31877668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy.
    Carrera-Aguado I; Marcos-Zazo L; Carrancio-Salán P; Guerra-Paes E; Sánchez-Juanes F; Muñoz-Félix JM
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular mechanisms underlying neutrophil infiltration in vessel co-opting colorectal cancer liver metastases.
    Rada M; Hassan N; Lazaris A; Metrakos P
    Front Oncol; 2022; 12():1004793. PubMed ID: 36330498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor vessel co-option: The past & the future.
    Cuypers A; Truong AK; Becker LM; Saavedra-García P; Carmeliet P
    Front Oncol; 2022; 12():965277. PubMed ID: 36119528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiopoietin-1 Upregulates Cancer Cell Motility in Colorectal Cancer Liver Metastases through Actin-Related Protein 2/3.
    Rada M; Kapelanski-Lamoureux A; Tsamchoe M; Petrillo S; Lazaris A; Metrakos P
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies.
    Lazaris A; Amri A; Petrillo SK; Zoroquiain P; Ibrahim N; Salman A; Gao ZH; Vermeulen PB; Metrakos P
    J Pathol Clin Res; 2018 Jul; 4(3):184-192. PubMed ID: 29654716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications and mechanism of histopathological growth pattern in colorectal cancer liver metastases.
    Kong BT; Fan QS; Wang XM; Zhang Q; Zhang GL
    World J Gastroenterol; 2022 Jul; 28(26):3101-3115. PubMed ID: 36051338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases.
    Leduc S; Nguyen HL; Richard F; Zels G; Mahdami A; De Schepper M; Maetens M; Pabba A; Jaekers J; Latacz E; Bohlok A; Vanderheyden E; Van Brussel T; Boeckx B; Schepers R; Lambrechts D; Dirix L; Larsimont D; Vankerckhove S; Lucidi V; Topal B; Bachir I; Donckier V; Floris G; Vermeulen P; Desmedt C
    Clin Exp Metastasis; 2024 Mar; ():. PubMed ID: 38548918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
    Coelho AL; Gomes MP; Catarino RJ; Rolfo C; Lopes AM; Medeiros RM; Araújo AM
    Oncotarget; 2017 Jun; 8(24):39795-39804. PubMed ID: 26950275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases.
    Galjart B; Nierop PMH; van der Stok EP; van den Braak RRJC; Höppener DJ; Daelemans S; Dirix LY; Verhoef C; Vermeulen PB; Grünhagen DJ
    Angiogenesis; 2019 May; 22(2):355-368. PubMed ID: 30637550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vessel co-option and resistance to anti-angiogenic therapy.
    Kuczynski EA; Reynolds AR
    Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular co-option in resistance to anti-angiogenic therapy.
    Ribatti D; Annese T; Tamma R
    Front Oncol; 2023; 13():1323350. PubMed ID: 38148844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
    Frentzas S; Simoneau E; Bridgeman VL; Vermeulen PB; Foo S; Kostaras E; Nathan M; Wotherspoon A; Gao ZH; Shi Y; Van den Eynden G; Daley F; Peckitt C; Tan X; Salman A; Lazaris A; Gazinska P; Berg TJ; Eltahir Z; Ritsma L; Van Rheenen J; Khashper A; Brown G; Nystrom H; Sund M; Van Laere S; Loyer E; Dirix L; Cunningham D; Metrakos P; Reynolds AR
    Nat Med; 2016 Nov; 22(11):1294-1302. PubMed ID: 27748747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.